Greek patients face significant hurdles in accessing the latest pharmaceutical treatments, even though the country approves them quicker than the European average.
A new study reveals a critical gap between drug availability and patient access in Greece.
The Hellenic Association of Pharmaceutical Companies (SFEE) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) conducted a series of studies alongside research firm IQVIA. The findings paint a concerning picture:
- Only 20% of New Drugs Reach Patients: Just one in five new pharmaceutical drugs approved by the European Medicines Agency (EMA) makes it to Greek patients.
- Funding Shortfall Limits Access: Greece spends 70% less on pharmaceuticals compared to the European average, severely impacting patient care. Per capita spending on medications falls short by a significant margin compared to other European countries.
- Delays in Reimbursement: Even when drugs reach Greece, lengthy pricing and reimbursement processes create further barriers for patients.
- Limited Availability: Only 52% of reimbursed innovative drugs are fully available, with delays impacting combination therapies. Oncology drugs receive some prioritisation.
While Greece approves new drugs faster than the European average (587 days vs. 643 days), financial constraints and a complex reimbursement system prevent patients from benefiting.
The study highlights the need for a multi-pronged approach:
- Increased Funding: Greece needs to significantly increase its pharmaceutical budget to ensure wider access to new treatments.
- Streamlined Reimbursement: A faster and more efficient pricing and reimbursement process is crucial to bridge the gap between availability and patient access.
- Improved Business Environment: SFEE argues that the current business environment for pharmaceutical companies is unsustainable, calling for reforms to attract investment.
The lack of access to innovative treatments significantly impacts Greek patients.
(Source: To Vima)